Date: 2014-11-19
Type of information: Nomination
Compound: chief medical officer
Company: Cortendo (Sweden)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 19, 2014, Cortendo announced the appointment of Ruth Thieroff-Ekerdt, M.D., as Chief Medical Officer effective December 15, 2014. Dr. Thieroff-Ekerdt brings more than 25 years experience across diverse therapeutic areas and orphan diseases in all aspects of drug discovery, development and regulatory approval. She will oversee Cortendo’s Phase 3 SONICS trial for COR-003 (levoketoconazole) in Cushing’s syndrome and all other Cortendo R&D programs. Most recently, Dr. Thieroff-Ekerdt was Chief Medical Officer at Aptalis Pharmaceuticals, which was acquired in February 2014 by Forest Laboratories for $2.9 billion. Prior to joining Aptalis, Dr. Thieroff-Ekerdt was Chief Medical Officer at Eurand Pharmaceuticals, and she held positions of increasing leadership in clinical and research functions at Bayer Consumer Care, Berlex Inc., and Schering AG. Dr. Thieroff-Ekerdt received her M.D. as well as a Dr. med degree from the Free University Berlin in Germany. She has pursued additional specialization in pharmacology and toxicology, including training in clinical pharmacology.
Financial terms:
Latest news:
Is general: Yes
